Skip to main content

GSK plc 6-K, filed Oct 26, 2026

GSK plc (GSK)

6-K 2026-10-26 For: 2026-10-26
View Original
Added on October 26, 2026

About this 6-K

GSK plc filed this 6-K on October 26, 2026.

GSK plc reported interim AZUR-1 results: 76% of evaluable patients achieved complete response to Jemperli monotherapy; independent review showed 47% achieved sustained cCR12, with no recurrences among responders after median follow-up of more than two years. AI summary